Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CG Oncology, Inc. (CGON : NSDQ)

• Company Description    CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $62.24 Daily Weekly Monthly 20 Day Moving Average: 1,030,637 shares Shares Outstanding: 88.64 (millions) Market Capitalization: $5,516.98 (millions) Beta: 0.28 52 Week High: $80.97 52 Week Low: $35.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.16% -15.72% 12 Week -9.95% -15.07% Year To Date 49.90% 32.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3000 PEGASUS PARK DRIVE SUITE 1640 - DALLAS,TX 75247 USA ph: 949-409-3700 fax: - ir@cgoncology.com https://cgoncology.com

• General Corporate Information    Officers Arthur Kuan - Chief Executive Officer and Chairman Jim DeTore - Interim Principal Financial and Accounting Officer Susan Graf - Director Brian Liu - Director James J. Mule - Director Peer Information CG Oncology, Inc. (CORR.) CG Oncology, Inc. (RSPI) CG Oncology, Inc. (CGXP) CG Oncology, Inc. (BGEN) CG Oncology, Inc. (GTBP) CG Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 156944100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 88.64 Most Recent Split Date: (:1) Beta: 0.28 Market Capitalization: $5,516.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.90 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.33 Price/Cash Flow: - Price / Sales: 885.83 EPS Growth vs. Year Ago Period: -66.67% vs. Previous Quarter: -26.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 6.83% ROE 09/30/26 - - 06/30/26 - -25.20 03/31/26 - -23.33 ROA 09/30/26 - - 06/30/26 - -23.98 03/31/26 - -22.24 Current Ratio 09/30/26 - - 06/30/26 - 22.22 03/31/26 - 31.30 Quick Ratio 09/30/26 - - 06/30/26 - 22.20 03/31/26 - 31.25 Operating Margin 09/30/26 - - 06/30/26 - -3,602.68 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - -3,602.68 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - -3,602.68 03/31/26 - -3,682.61 Book Value 09/30/26 - - 06/30/26 - 11.67 03/31/26 - 12.40 Inventory Turnover 09/30/26 - - 06/30/26 - 8.29 03/31/26 - 6.68 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.29 03/31/26 - 0.27

Powered by Zacks Investment Research ©